- Home
- INBX vs VOR Comparison
INBX vs VOR Comparison
Compare INBX & VOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INBX | VOR |
|---|---|---|
| Founded | 2010 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.4B |
| IPO Year | 2024 | 2021 |
Fundamental Metrics
Financial Performance| Metric | INBX | VOR |
|---|---|---|
| Price | $110.27 | $22.35 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 10 |
| Target Price | ★ $150.00 | $45.33 |
| AVG Volume (30 Days) | 317.9K | ★ 697.7K |
| Earning Date | 05-15-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,300,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 550.00 | N/A |
| 52 Week Low | $26.19 | $6.50 |
| 52 Week High | $155.29 | $49.95 |
Technical Indicators
Market Signals| Indicator | INBX | VOR |
|---|---|---|
| Relative Strength Index (RSI) | 51.54 | 47.59 |
| Support Level | $70.23 | $21.90 |
| Resistance Level | $131.01 | $24.44 |
| Average True Range (ATR) | 10.16 | 1.13 |
| MACD | -1.30 | -0.19 |
| Stochastic Oscillator | 43.91 | 12.44 |
Price Performance
Historical ComparisonAbout INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.
About VOR Vor Biopharma Inc.
Vor Biopharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of autoimmune diseases. Its program, telitacicept, is a potential first- and best-in-class dual BAFF/APRIL inhibitor designed to suppress the signaling pathways that drive the maturation, proliferation, and survival of harmful B cells, including self-reactive B cells, thereby reducing autoantibody production and preventing downstream tissue damage.